Patents Assigned to ENTEROME S.A.
  • Antigenic peptides for treatment of B-cell malignancy
    Patent number: 11759508
    Abstract: The present invention relates to antigen-based immunotherapy, in particular cancer immunotherapy. In particular, the present invention provides antigenic peptides, which are distinct from, but have amino acid similarity to, especially share the same core sequence with epitopes of human tumor antigens. The present invention further provides immunogenic compounds, nanoparticles, cells and pharmaceutical compositions comprising such antigenic peptides and nucleic acids encoding such antigenic peptides.
    Type: Grant
    Filed: May 2, 2022
    Date of Patent: September 19, 2023
    Assignee: ENTEROME S.A.
    Inventors: Laurent Chene, Francesco Strozzi, Joao Gamelas Magalhaes, Guillaume Kulakowski
  • Microbiota sequence variants of tumor-related antigenic epitopes
    Patent number: 11712465
    Abstract: The present invention relates to cancer immunotherapy, in particular to sequence variants of tumor-related antigenic epitope sequences. Namely, the present invention provides a method for identification of microbiota sequence variants of tumor-related antigenic epitope sequences. Such microbiota sequence variants are useful for the preparation of anticancer medicaments, since they differ from self-antigens and, thus, they may elicit a strong immune response. Accordingly, medicaments comprising microbiota sequence variants, methods of preparing such medicaments and uses of such medicaments are provided.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: August 1, 2023
    Assignee: ENTEROME S.A.
    Inventors: Laurent Chene, Alessandra Cervino, Francesco Strozzi, Celia Mendez, Christophe Bonny
  • Immunogenic Compounds For Treatment Of Adrenal Cancer
    Publication number: 20230105457
    Abstract: The present invention relates to antigen-based immunotherapy targeting interleukin 13 receptor alpha 2 (IL13RA2), BIRC5 and/or FOXM1 for treatment of adrenal cancers. In particular, the present invention provides the use of a (poly)peptide comprising an epitope of IL13RA2, BIRC5 and/or FOXM1 or a sequence variant thereof for treatment of an adrenal cancer. Moreover, the present invention also provides combinations of the (poly)peptide comprising an epitope of IL13RA2, BIRC5 and/or FOXM1 or a sequence variant thereof with (poly)peptides comprising other epitopes or sequence variants thereof for treatment of adrenal cancers.
    Type: Application
    Filed: October 16, 2020
    Publication date: April 6, 2023
    Applicant: ENTEROME S.A.
    Inventors: Laurent CHENE, Jan FAGERBERG
  • Microbiota-Derived Proteins Inducing Il-10 Release From Human Cells And Uses Thereof
    Publication number: 20230068615
    Abstract: The present invention relates to microbiota-derived proteins, which are capable of inducing and/or enhancing secretion of IL-10 from human cells. Accordingly, the present invention provides microbial proteins, and fragments and sequence variants thereof, which stimulate IL-10 release from human immune cells. The present invention also relates to nucleic acids encoding such proteins, cells expressing such proteins, respective pharmaceutical compositions and uses thereof.
    Type: Application
    Filed: January 22, 2021
    Publication date: March 2, 2023
    Applicant: ENTEROME S.A.
    Inventors: Antoinetta CULTRONE, Laurent CHENE, Francesco STROZZI, Christophe BONNY
  • Immunogenic compounds for cancer therapy
    Patent number: 11478537
    Abstract: The invention relates to an immunogenic compound comprising an antigenic peptide having amino acid similarity with a tumor antigen, which antigenic peptide is selected in the group consisting of sequences described in the specification.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: October 25, 2022
    Assignee: ENTEROME S.A.
    Inventors: Laurent Chene, Alban Mathieu, Matthieu Pichaud, Francesco Strozzi
  • Immunogenic compounds for cancer therapy
    Patent number: 11478538
    Abstract: The invention relates to an immunogenic compound comprising an antigenic peptide having amino acid similarity with a tumor antigen, which antigenic peptide is selected in the group consisting of peptides having amino acid similarity with IL13RA2, the said antigenic peptide being selected in the group consisting of sequences described in the specification.
    Type: Grant
    Filed: October 9, 2017
    Date of Patent: October 25, 2022
    Assignee: ENTEROME S.A.
    Inventors: Laurent Chene, Alban Mathieu, Matthieu Pichaud
  • Microbiota Sequence Variants Of Tumor-Related Antigenic Epitopes
    Publication number: 20200025774
    Abstract: The present invention relates to cancer immunotherapy, in particular to sequence variants of tumor-related antigenic epitope sequences. Namely, the present invention provides a method for identification of microbiota sequence variants of tumor-related antigenic epitope sequences. Such microbiota sequence variants are useful for the preparation of anticancer medicaments, since they differ from self-antigens and, thus, they may elicit a strong immune response. Accordingly, medicaments comprising microbiota sequence variants, methods of preparing such medicaments and uses of such medicaments are provided.
    Type: Application
    Filed: October 9, 2017
    Publication date: January 23, 2020
    Applicant: ENTEROME S.A.
    Inventors: Laurent CHENE, Alessandra CERVINO, Francesco STROZZI, Celia MENDEZ, Christophe BONNY